Mark Robert Baker, CEO at PROGENICS PHARMACEUTICALS INC (PGNX), bought 348 shares at $9.97 ($4K) on 2012-04-25, disclosed to the SEC on 2012-04-27.
Scheduled purchase ($4k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.92 | 100 | $992 | 28.3% |
| 2 | $9.97 | 100 | $997 | 28.4% |
| 3 | $10.25 | 15 | $154 | 4.4% |
| 4 | $10.25 | 133 | $1K | 38.9% |
| Total | $10.07 avg | 348 | $4K | 100% |
| Filing → |
| PGNX | BUY | 2013-01-23 | $3K | — | Filing → |
| PGNX | BUY | 2012-12-26 | $3K | — | Filing → |
| PGNX | BUY | 2012-11-30 | $3K | — | Filing → |